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The prevalence of hepatitis B co-infection in a South African 
urban government HIV clinic
Cynthia Firnhaber, Anne Reyneke, Doreen Schulze, Babatyi Malope, Mhairi Maskew, Patrick MacPhail, Ian Sanne,  
Adrian Di Bisceglie
There are an estimated 350 million hepatitis B carriers 
worldwide. Hepatitis B transmission is similar to that of HIV; 
therefore, co-infection with HIV and hepatitis B is not unusual. 
The prevalence of mono-infection with hepatitis B in South 
Africa has been estimated as approximately 10% in the rural 
population and 1% in urban areas.1,2 The exact prevalence 
of hepatitis B in the HIV population has not been accurately 
established.
The guidelines for the South African HIV Comprehensive 
Care, Management and Treatment (CCMT) programme do 
not include viral hepatitis studies.3 Hepatitis B serological 
tests are done only if serum aminotransferases are elevated 
in the absence of another known cause (e.g. tuberculosis 
and concomitant medications). We found three studies that 
documented the South African prevalence of HIV/HBV 
coinfection: a retrospective unmatched control laboratory-based 
study;4 a prospective study looking at HIV patients admitted 
to hospital;5 and a retrospective study of a cohort emanating 
from South African goldmines.6 The rate of co-infection varied 
from 6% to 17%. No prospective study has evaluated the rate 
of hepatitis B virus (HBV) infection in a CCMT outpatient 
antiretroviral (ARV) clinic in South Africa.
Lamivudine is used in the treatment of both HIV and 
hepatitis B7,8 and is widely used as first-line ARV therapy in 
most African settings. Hepatitis flares have been reported both 
on initiation of lamivudine and on its discontinuation in HIV-
seropositive patients.9,10 Lamivudine’s safety and tolerability 
in HBV/HIV co-infection have not been described in resource-
limited settings. Our study describing the baseline prevalence 
of HIV/hepatitis B co-infection in a Johannesburg CCMT clinic 
forms part of a PEPFAR ([USA] President’s Emergency Plan for 
AIDS Relief) evaluation to examine the prevalence of  
co-infection and the 6-month safety and tolerance of 
lamuvidine in this co-infected population.
Methods
Subjects
Patients from an outpatient PEPFAR-supported HIV clinic in 
a regional academic hospital in Johannesburg were invited 
to participate in this study. Patients who were about to 
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Objective. There are an estimated 350 million hepatitis B 
carriers worldwide. In South Africa the prevalence of mono-
infection with hepatitis B has been estimated to range from 
1% in urban areas to approximately 10% in rural areas. The 
exact prevalence of hepatitis B in the HIV-infected population 
has not been well established. Hepatitis B screening is not 
standard practice in government HIV clinics. Co-infection 
with hepatitis B and HIV can influence antiretroviral 
treatment and prognosis of both diseases. The purpose of 
this study was to evaluate the prevalence of hepatitis B/HIV 
coinfection.
Design. This is believed to be the first prospective 
observational report on the prevalence of hepatitis B/HIV 
co-infection in South Africa. Patients on whom hepatitis 
B serological tests could not have been done previously 
were recruited from an HIV clinic in a regional hospital in 
Johannesburg. Standard hepatitis B serological tests were 
performed.
Results. Five hundred and two participants were screened. 
The cohort’s average age was 37±9 years and the average CD4 
count was 128 cells/µl. Twenty-four (4.8%) were hepatitis B 
surface antigen positive. Nearly half (47%) of the participants 
showed some evidence of hepatitis B exposure. The risk 
of hepatitis B co-infection was not significantly different 
when analysed in terms of sex, race, CD4 count or age. 
Liver function tests were not a good predictor of hepatitis B 
infection.
Conclusion. The rate of hepatitis B infection, as defined 
by hepatitis B surface antigen positivity, in HIV-infected 
individuals in urban South Africa was 5 times the rate in 
people who were not HIV-infected. A 5% rate of hepatitis 
B/HIV co-infection is a reason to increase the accessibility of 
tenofovir/emtricitabine (Truvada) for first-line treatment for 
this population.
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initiate ARV therapy according to the SA CCMT guidelines 
were informed about hepatitis B and HIV coinfection (CD4 
counts <200/µl or World Health Organization (WHO) III or 
IV staging). A total of 502 people agreed to undergo hepatitis 
B screening and gave written informed consent. The study 
was approved by the University of the Witwatersrand ethics 
committee and the Saint Louis University Institutional Review 
Board. The patients had to be willing to start an ARV regimen 
containing lamivudine. Reasons given for not participating 
in the study included wanting additional time to listen to the 
education on hepatitis B or to sign consent, poor understanding 
of the study, not wanting an extra blood sample taken, and 
feeling too ill.
Laboratory analysis
Serological testing included hepatitis B surface antigen 
(HBsAg), hepatitis B core antibody (anti-HBc), hepatitis B 
surface antibody (anti-HBs) and hepatitis early (e) antigen 
HBeAg) and antibody (anti-HBe) using the Axsym assay 
with the MEIA methodology (Abbott Laboratories, Ill., USA). 
Hepatitis B viral DNA (HBV DNA) was measured using the 
Roche Cobas Amplicor quantitative assay (Roche Diagnostic 
Systems, Branchburg, NJ). Patients who were seropositive to 
HBsAg were considered positive, enrolled in the next phase of 
the study and initiated on highly active antiretroviral treatment 
(HAART) of lamivudine, stavudine and efavirenz, the first-line 
ARV regimen in the South African CCMT programme. Blood 
was drawn at the enrolment visit for HBeAg and anti-HBc, 
HBV DNA, hepatitis C and D antibody, full blood count, serum 
electrolytes, serum aminotransferases, urinalysis, CD4 cell 
count and HIV viral load.
Results
The study comprised 502 participants, 354 (71%) females and 
148 (29%) males, with a mean age (± significant deviation 
(SD)) of 37±9.1 years. Female subjects were significantly 
younger than male subjects (35.8±8.5 years v. 39.9±9.7 years, 
p<0.0001). The female-to-male ratio and the average age of 
the participants reflect the demographics of the larger clinic, 
which mirrors the demographic pattern of the South African 
HIV epidemic. The mean CD4 count was 128.6±84.4, and was 
similar in males and females (p>0.84). The majority (94.6%) of 
the 502 patients were black; the rest (27) were either coloured 
or white (Table I). As shown in the table, 24 (4.8%) of the 502 
patients screened were seropositive for HBsAg. Fifty-three 
(10.5%) of the patients had isolated core antibodies without 
any other markers of HBV infection. Forty-seven per cent of 
the cohort demonstrated some exposure to hepatitis B. Only 
2.6% of the cohort had serological findings consistent with 
vaccination (anti-HBs alone).
The risk for hepatitis B infection was not significantly 
different when analysed in terms of sex (odds ratio (OR) 0.7 
(95% confidence interval (CI) 0.3 - 1.6), p>0.4) or racial group 
(OR (95% CI) 1.3 (0.2 - 10.1), p>0.7). There was no statistical 
difference in hepatitis B serological results in terms of CD4 
count, age or gender, except that men were statistically more 
likely to have an isolated core antibody (p<0.054) (Table I) 
and were 1.6 times more likely to be positive overall to any 
hepatitis B serological test (positive for anti-HBs or anti-HBc or 
HBsAg combined) (OR (95% CI) 1.6 (1.1 - 2.3), p<0.012 (Table 
I)).
Of the 24 subjects who were seropositive to HBsAg, 
19 qualified for the observational study. The baseline 
demographics of the smaller cohort were not statistically 
significantly different from the main cohort in terms of mean 
baseline CD4 count and age.
We compared the standard laboratory results with HBeAg-
negative and HBeAg-positive patients who were HBsAg 
positive. E antigen is thought to be a marker of hepatitis B 
replication. Of the 19 who were HBsAg positive, 9 were e-
Table I. Demographic and baseline information of all subjects screened for HBV
         Screening
      All (502)  Female (354) Male (148) Significance 
Demographic
 information Age (mean (±SD))       37.0 (9.1)    35.9 (8.6)    39.9 (9.7) p<0.0001
  CD4 counts (mean (±SD))  128.6 (84.4) 129.1 (78.6) 127.4 (97.1)    p=0.84
  Race
     Black (f:m ratio 2.5:1)              475    338 (71.2)    137 (28.8) p<0.0001
     Other (mixed race or Caucasian)                27      16 (59.3)      11 (40.7)    p=0.33
     (f:m ratio 1.4:1)
HBV
seropositive  HB surface antigen positive         24 (4.8)    15 (4.2%)      9 (6.1%)
markers  HB surface antibodies only      13 (2.6%)       7 (2.0%)      6 (4.1%)
  HB core antibodies only    53 (10.6%)     29 (8.2%)  24 (16.2%) p=0.053
  Both HB surface and core antibodies 124 (24.7%)   88 (24.9%)  36 (24.3%)
  Negative to all   288 (57.4%) 215 (60.7%)  73 (49.3%)
Positive to  Positive    214 (42.6%) 139 (39.3%)  75 (50.7%) p=0.019
any marker
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antigen positive (7 out of 9 had HBV DNA). Ten were e-antigen 
negative, and 5 of these patients had HBV DNA. There were 
two statistically different laboratory parameters between 
the e-antigen-positive and negative patients. The e-antigen- 
negative patients had higher CD4 counts (189.4 v. 113.11 
cells/µl; p=0.0316) and higher total proteins. There were no 
statistical differences in HIV viral load, liver function tests or 
HBV viral load (although e-antigen-positive patients tended to 
have higher HBV viral loads) between e-antigen-positive and 
negative patients. None of the participants was found to be 
hepatitis C or D positive.
When comparing hepatitis B DNA viral load (HBV) to CD4 
count or HIV viral load, there was no statistical difference. The 
only statistical difference was seen in a slightly higher average 
in the alanine transaminase (ALT) levels (mean 46±21.6) in the 
high detectable HBV viral loads category (Table II). However, 
liver function tests overall were not good predictors of hepatitis 
B infection. All of the 19 people who were positive for HBsAg 
had normal or slightly elevated serum aminotransferases (Table 
III).
Discussion
Co-infection with HIV and hepatitis B is not well described 
in southern Africa, but the rate is anticipated to be high as 
the viruses have similar modes of transmission. Hepatitis B 
prevalence in the non-HIV-infected population is about 10% in 
rural South African areas and about 1% in urban areas.1,2 We 
have shown that the urban South African co-infection rate is 
five times that found in the non-HIV-infected population. Our 
serological study also demonstrates that approximately 50% 
of HIV-seropositive patients have been exposed to hepatitis 
B. The South African paediatric immunisation programme for 
hepatitis B started in 1995; this prevention strategy would not 
be reflected in this cohort.
At present, the SA CCMT guidelines do not recommend 
routine testing for hepatitis B co-infection. In our study, there 
were no other markers of hepatitis B infection, and liver 
function tests were not an adequate indicator of infection. This 
prevalence rate, determined only by surface antigen serology, 
may be falsely low as HBV DNA has been commonly reported 
in HIV-seropositive patients with isolated core antibody.11 
If this is the case, the prevalence of co-infection would be 
closer to 15% in this urban population. Real-time hepatitis B 
polymerase chain reaction studies on the serum of screened 
patients with isolated core antibody are currently being done in 
this cohort.
Hepatitis B can be treated with lamivudine, which is used 
as first-line treatment in the HIV treatment programme 
and is well tolerated. However, there are reports of liver 
complications when treating HIV/hepatitis B co-infection with 
the addition of antiretroviral therapy for HIV and removal 
of lamivudine, which can cause liver inflammation and, 
rarely, liver failure.10 Another complication is that lamivudine 
resistance also develops at a quicker rate in HIV-seropositive 
patients. Therefore, during the first year of lamivudine-
containing ARV treatment, most patients will have adequate 
treatment of their hepatitis B. However, by the second year, 
approximately 40% of these patients will have developed 
resistance.9,12 The WHO guidelines recommend dual therapy 
in HIV patients: either tenofovir/lamivudine or tenofovir/
emtricitabine (Truvada )12 to reduce the risk of developing 
resistance, as tenofovir also treats hepatitis B.13
Possible limitations of this study were:
1. The low average CD4 count, as these people were 
attending the educational session to start ARVs as per the 
Table III. Liver transaminase results in HIV and  
hepatitis B co-infected surface antigen-positive patients
Levels of liver transaminase                  Number of patients 
AST 
Grade 1 elevation (50 - 100)                          8 (42.11)
Normal range (5 - 40)                        11 (57.89)
ALT 
Grade 1 elevation (50 - 100)                         3 (15.79)
Normal range ( 5 - 40)                       16 (84.21)
AST = aspartate transaminase; ALT = alanine transaminase.
Table II. HBV viral load v. CD4 count and liver function tests (mean (SD))
      HBV viral load
              Low detectable          High detectable
          Undetectable (0)      (<200/µl)            (≥200/µl)         p-value
Total (N)=18        5            4    9 
CD4 count result              148.8 (63.8)   209.3 (39.99)           138.1 (95.5)         0.34
Log HIV viral load                  11.8 (1.7)       11.9 (1.68)              12.1 (1.1)         0.95
ALP   67.8 (8.5)     75.2 (30.13)           114.2 (78.3)         0.32
AST   30.2 (8.7)     47.0 (19.78)             60.1 (21.3)         0.074
ALT    28 (12.2)     23.4 (12.07)             46.1 (21.6)         0.034*
Albumin   38.2 (4.1)       33.8 (7.37)               32.7 (6.1)         0.267
Haemoglobin  11.7 (2.1)       14.1 (2.47)               11.6 (2.1)         0.159
White cell count   3.3 (0.7)       4.83 (1.58)               4.51 (1.6)         0.24
ALP = alkaline phosphatase; AST = aspartate transaminase; ALT = alanine transaminase.
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government programme. How their immune status could affect 
their serological findings is unknown. With immunodeficiency, 
there could theoretically be a decrease in production of 
antibodies to hepatitis B, leading to misdiagnosis of hepatitis B 
status.
2. Hepatitis B viral loads were not done on all screened 
patients owing to limited resources. If the study had had the 
capacity to perform HBV viral loads, this would have clarified 
the actual prevalence of hepatitis B exposure and chronic 
carrier status.
3. Negative or positive e-antigen status did not correlate 
with HBV replication in our cohort, indicating that e-antigen 
status may not be an adequate surrogate marker of replicating 
hepatitis B DNA. Black Africans seroconvert from e antigen 
to e antibody far earlier than other populations.14,15 This may 
be due to the presence of one or more mutations in one of the 
following areas: the precore/core, the basic core promoter, the 
Kozak sequence and/or the bulge of the RNA encapsidation 
signal (personal communication, Professor Michael Kew).
What impact these complications have on ARV treatment 
programmes in southern Africa is unclear. Monitoring of this 
cohort for these complications is under way and it is hoped 
will provide some answers. At present, HIV patients with HBV 
coinfection should be monitored carefully.
Conclusions
The rate of co-infection with hepatitis B/HIV as defined by 
HBsAg is five times the rate of hepatitis B infection in the non-
HIV population in urban South Africa; further investigation 
is necessary to evaluate the possibility of occult hepatitis B 
infection in patients with an isolated core antibody. A 5% 
prevalence of co-infection in government ARV urban clinics is a 
reason to consider evaluating the cost of hepatitis B serological 
tests, hepatitis B vaccination (50% of the cohort showed no 
serological exposure to hepatitis B) and initiating a tenofovir/
emtricitabine backbone as an option for first-line ARV therapy 
in co-infected patients in government ARV clinics.
NIH/Pepfar Targeted Evaluations U01 A1-38858.
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